Abstract
Introduction Post-covid-19 syndrome, or Long covid (LC) refers to symptoms persisting 12 weeks after Covid-19 infection. LC comprises a wide range of dysautonomia symptoms, including fatigue, breathlessness, palpitations, dizziness, pain and brain fog. This study tested the feasibility and estimated the efficacy, of a Heart Rate Variability Biofeedback (HRV-B) technique via a standardised slow diaphragmatic breathing programme in individuals with LC.
Methods and Analysis LC patients underwent a 4-week HRV-B intervention for 10 minutes twice daily for a total of 4 weeks using the Polar H10 ECG (Electrocardiogram) chest strap and Elite HRV phone application. Outcome measures C19-YRSm (Yorkshire Rehabilitation Scale modified), EQ5D-5L (EuroQol 5 Dimensions), Composite Autonomic Symptom Score (COMPASS-31), WHO Disability Assessment Schedule (WHODAS), and Root Mean Square of Successive Differences between heartbeats (RMSSD) using a Fitbit device were completed before and after the intervention. The study was pre-registered at clinicaltrials.gov NCT05228665.
Results 13 participants (54% female, 46% male) completed the study with high levels of data completeness and adherence. There was a statistically significant improvement in C19YRS-m (p=0.001), EQ5D Global Health Score (p=0.009), COMPASS-31 (p=0.007), RMSSD (p=0.047) and EHODAS (p=0.02). Qualitative feedback suggested participants were able to use it independently, were satisfied with the intervention, and reported beneficial effects from the intervention.
Conclusion This is the first study in the literature to report that HRV-B is a feasible intervention for LC and seems to be potentially improving symptoms of LC and dysautonomia.
Strengths and limitations of the study
To our knowledge, this is the first study of HRV-B in long covid and dysautonomia and has shown the feasibility of a novel technology-based intervention in a home setting.
There was a statistically significant improvement in LC symptoms, functional ability, quality of life and dysautonomia scores.
The study provides an estimation of efficacy which will determine the sample size for a larger controlled trial in LC and dysautonomia.
The main limitation of this study is the small sample size and uncontrolled design which might not give us an accurate estimate of efficacy.
The sample was predominantly Caucasian participants, 54% of whom were female.
The take-up for HRV-B in those with a lack of experience in using digital technology and those from less privileged backgrounds is unknown.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study was pre-registered at clinicaltrials.gov NCT05228665
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/36410797/
Funding Statement
This research was supported by IAA EPSRC grant [Ref 112538] with the University of Leeds as the sponsor organisation and the Leeds Community Healthcare NHS Trust Covid Rehabilitation service as the research site organisation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Ethics and Dissemination The study received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271).
Data Availability
All data produced in the present study are available upon reasonable request to the authors
